Phase I/II Evaluation of Novel BTKi PRN1008 in R/R Primary or Secondary Immune Thrombocytopenia

December 7-10, 2019; Orlando, Florida
Early-stage data suggest rapid, durable activity of the novel Bruton tyrosine kinase inhibitor PRN1008 in heavily pretreated patients with relapsed/refractory ITP.
Format: Microsoft PowerPoint (.ppt)
File Size: 181 KB
Released: December 10, 2019

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower in partnership with Clinical Care Options.
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Celgene Corporation
Dova Pharmaceuticals, Inc.
Karyopharm Therapeutics
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Related Content

Downloadable resource from Clinical Care Options (CCO) to share with patients that covers the basics of hemophilia A and differences between available prophylaxis therapies

Glaivy Batsuli, MD Released: May 9, 2022

GVHD experts address key questions about the treatment of patients with graft versus host disease in this commentary from Clinical Care Options (CCO)

Corey Cutler, MD, MPH, FRCPC Released: May 4, 2022

From Clinical Care Options (CCO), video webinar on recent advances in management of acute and chronic GVHD for physicians, nurses, and pharmacists

Corey Cutler, MD, MPH, FRCPC David Miklos, MD, PhD Robert Zeiser, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: May 4, 2022 Expired: May 3, 2023

Downloadable slideset from a live webinar from Clinical Care Options (CCO) on the management of hemophilia A with nonfactor replacement therapies

person default Kayla Douglas, PharmD Released: April 27, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings